Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced that its Chief Scientific Officer, Ian Taylor, Ph.D., will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on September 10 at 2:25 p.m. ET. A live audio webcast will be available here and on Arvinas’ website. The company is focused on developing therapies for diseases like metastatic prostate cancer and ER+/HER2- breast cancer.

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15^th Annual BioPharma Virtual Conference on Thursday, September 10 at 2:25 p.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC^® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com

FAQ

What is the date and time of Arvinas' presentation at the Citi conference?

Arvinas' presentation at the Citi 15th Annual BioPharma Virtual Conference is scheduled for September 10 at 2:25 p.m. ET.

Who will represent Arvinas at the Citi BioPharma Conference?

Ian Taylor, Ph.D., the Chief Scientific Officer of Arvinas, will represent the company at the conference.

Where can I watch the Arvinas presentation live?

You can watch the live presentation of Arvinas at the Citi conference via a webcast available on their website.

What are Arvinas' clinical-stage programs?

Arvinas is developing ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for ER+/HER2- breast cancer.

What innovative technology does Arvinas use?

Arvinas utilizes a proprietary technology platform to develop PROTAC® targeted protein degraders, which degrade disease-causing proteins.